About this trial
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Patient Profile
This trial is for patients with Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK6482-022 |
|---|---|
| Number: | 21-37 |
| Full Title: | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) |
| Principal Investigator: | Prof Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: March 2022 Ireland: July 2022 |
| Global Recruitment Target: | 1600 |
|---|---|
| Ireland Recruitment Target: | 15 |